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Letters to the Editor 
Dear Editor 
Successful fibrin glue repair of iatrogenic bronchial 
rupture 
Bronchial rupture is a possible complication of rigid 
bronchoscopy, and rarely of endotracheal intubation 
with Carlens’ and Robertshow’s and even with poly- 
vinylchloride (PVC) endotrachael tubes. Until recently 
surgical repair has been the treatment of choice (1,2). 
Fibrin glue, an agent composed of thrombin III and 
fibrinogen has been used to close the postoperative 
bronchopleural fistulas (3-S). Its use for repair of 
iatrogenic bronchial rupture has not been reported in 
the literature. 
A 58-year-old male was admitted to hospital for 
investigation of a 2-month history of weight loss, 
exertional dyspnoea, haemoptysis, left back pain and 
a left hilar mass on his chest radiograph. Rigid 
bronchoscopy was performed under local anaesthesia 
with an 8.5 mm, 40 cm standart bronchoscope; while 
obtaining biopsy specimen with a rotating forceps 
from the tumour mass in the left upper lobe bronchus, 
a 5 mm horizontal rupture developed in the left main 
bronchus. Subcutaneous emphysema and dyspnoea 
developed quickly and the procedure was stopped 
immediately. Substernal pain, hoarseness and hypo- 
tension were the main manifestations and a chest CT 
showed pneumomediastinum (Fig. 1). The patient was 
carefully observed, and 6 h later, bronchoscopy was 
repeated and 0.5 ml fibrin glue (Tisseel) was directly 
delivered to the rupture area. Symptoms began to 
decrease immediately after the procedure, and his 
subcutaneous emphysema was gone by the 4th day. 
Chemotherapy and radiotherapy utilized to treat 
the patient’s limited disease small cell lung cancer 
(T4N2M0, Stage IIIb). During the 9 months since the 
rupture, no symptoms related to bronchial leakage 
have been reported. 
Fibrin glue was first used for repair of postoperative 
broncho-pleural fistulas by Hartmann and colleagues 
in 1977. It has been used in several cases and proved to 
be useful in experimental studies (69). The agent 
covers the rupture as a plug initially and then inflam- 
mation develops, proliferation of the mucosa and 
fibrosis occurs (10). The size of the plug should be large 
enough to close the rupture, but should not prevent the 
Fig 1 Computed tomogram taken 2 h after the rupture, showed pneumomediastinum. 
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drainage of the bronchus. For this reason, 0.5 ml fibrin 
glue was administered in our case. In the following 6 
months, although radiotherapy was applied to the 
area, no relapse was observed and this reflected the 
reliability of the procedure. 
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Dear Editor 
Chemoprophylaxis for tuberculosis 
Dr Israel’s sensitive and sensible editorial on 
chemoprophylaxis for tuberculosis (Respiratory 
Medicine, February 1993) sounds caution with regard 
to isoniazid (INH) and opens questions that we have 
been considering for some time. Although the oft- 
quoted American evidence suggests that a short 
course of INH considerably reduces cases of clinically 
manifest disease over the 2 years following known 
contact with an infectious index case, the frequently 
drawn conclusion that this is evidence of bacterial per- 
sistors being destroyed must be questioned. The cases 
prevented are likely to be those in an early stage of 
development of disease due to exogenous infection in 
persons in whom persistor bacilli have not become 
established. There is no reason to think that INH can 
prevent cases arising from endogenous activation, 
except during the time that the drug is being taken. 
If this is so, then a short course of INH in persons 
co-infected with HIV may prove disappointing. 
Persistor status is a balance between the propensity 
of the tubercle bacillus to multiply and cause disease, 
and the ability of T helper cell mediated immunity to 
hold the organisms in stasis (1). We know that this 
balance tips in favour of the bacillus very early in HIV 
infection, apparently being one of the earliest immune 
functions lost. On theoretical grounds, arming the 
immune system to destroy bacilli already in stasis 
should be an option for prophylaxis potentially just as 
effective in persons infected with drug resistant bacilli 
as in those infected with drug susceptible organisms. 
Sadly, we know BCG not to be capable of this, but 
progress need not end there. Although we have no 
more than fragmentary evidence that it can actually be 
done, investigations into the action of immunotherapy 
with Mycobacterium waccae for clinical tuberculosis 
suggest that the mechanisms induced should also be 
active in destroying persistor tubercle bacilli before 
they give rise to disease. Studies have already started to 
evaluate this possibility in close contacts of tubercu- 
losis patients and may soon be applied to tuberculin 
positive HIV seropositive patients. 
The studies upon which this proposition is based are 
just beginning to appear in the literature, and the 
evidence in support of the value of immunotherapy in 
the treatment of pulmonary tuberculosis, both drug- 
resistant and susceptible, is growing almost daily. 
Studies are completed, or in progress in Kuwait (2), 
Gambia (3), Iran (4), Nigeria (5), Romania and 
Vietnam, and anecdotal evidence on small numbers of 
cases has been received from Sweden, India and the 
U.K. 
The mechanism of its action appears to be an 
enhancement of recognition of common mycobacterial 
antigens, together with a switch in T cell function from 
the equivalent of THY to THY. Work in progress 
suggests that this switch involves changes in the 
cytokine-endocrine axis, which modulate the subsets of 
helper T cells generated in response to mycobacterial 
antigens. 
Enhanced THY activity would be precisely what is 
needed to hold bacilli in persistance, or even to lead to 
their true elimination. The lack of toxicity or deleterious 
side effects of autoclaved M. vaccae (NCTC 11659) are 
